Clue App BBB Rating and Consumer Complaint Trends: What Women Should Know

Is Clue a Legitimate App?

Clue is a real, functioning product built by BioWink GmbH, a Berlin-based femtech company founded in 2012. The standard Clue cycle-tracking app has been downloaded more than 100 million times globally, and the company's science team has published peer-reviewed research on cycle variability in collaboration with academic institutions. Legitimacy, in the sense of the company existing and the product working, is not in serious question.

What deserves scrutiny is something different: whether the app delivers on its specific promises around accuracy, privacy, and subscription value, and whether its claims are appropriately scoped for the health decisions women make with cycle data.

What "Legitimate" Actually Means for a Health App

A cycle-tracking app occupies a grey zone in health regulation. The base Clue app is classified as a general wellness product, not a medical device, meaning the FDA does not require the company to prove accuracy claims the way it would for a diagnostic tool. That distinction matters enormously if you are using the app to time unprotected sex, manage PCOS cycles, or understand perimenopausal bleeding patterns.

Clue Birth Control, the separate FDA-cleared digital contraceptive, received 510(k) clearance (K173542) as a Class II device. The clearance covers a very specific algorithm and use case. It is not interchangeable with the standard free or Plus subscription.

Regulatory Standing at a Glance

| Feature | Standard Clue App | Clue Birth Control | |---|---|---| | FDA cleared | No | Yes (K173542) | | HIPAA governed | No | No (EU company) | | GDPR governed | Yes | Yes | | Marketed as contraceptive | No | Yes | | Free tier available | Yes | No |

BBB Status and Formal U.S. Complaint Record

Clue has no Better Business Bureau accreditation and no active BBB business profile in the United States as of January 2025. This is not unusual for European technology companies that distribute apps through the Apple App Store and Google Play rather than operating a U.S. Storefront directly.

The practical consequence: women who have billing disputes cannot escalate through BBB mediation in the same way they could with a U.S.-domiciled company. Subscription billing goes through Apple or Google, which means Apple's and Google's dispute processes apply, not Clue's own customer service pipeline. That indirect billing structure is itself a source of confusion documented in user reviews.

What the FTC Record Shows

The Federal Trade Commission's Consumer Sentinel Network does not show a pattern of Clue-specific enforcement actions as of this writing. The FTC's broader 2023 health breach notification guidance does apply to apps that collect sensitive reproductive health data, and Clue's data-sharing practices would fall under that scrutiny if the company were to sell or disclose cycle data to third parties. Clue has publicly stated it does not sell personal health data, and the company's GDPR obligations under German law create enforceable restrictions that go beyond what most U.S. Wellness apps face.

State-Level Consumer Protection

Several U.S. States, including California under the California Consumer Privacy Act (CCPA), give residents the right to request deletion of their health data from app companies regardless of where those companies are based. Women in California, Colorado, Connecticut, and Virginia have actionable rights over their cycle data held by Clue, even though the company is German.

The Most Common Consumer Complaints

App store reviews, Reddit threads in r/birthcontrol and r/PCOS, and Trustpilot submissions converge on four recurring complaint categories. These are not isolated incidents, they appear consistently across years and platforms.

1. Subscription Billing and Cancellation

The single most frequent complaint category involves difficulty canceling Clue Plus subscriptions and unexpected renewal charges. Because billing is managed through Apple or Google rather than directly by Clue, users report that canceling through Clue's in-app settings does not actually cancel the underlying store subscription. The correct cancellation path runs through the device's App Store or Google Play subscription settings, not the Clue app menu. This mismatch trips up a meaningful proportion of users who believe they have canceled and then receive a renewal charge.

Remedy: if you subscribed through the iPhone App Store, cancel at Settings > [your name] > Subscriptions > Clue. Do not rely on the in-app cancel option as your only step.

2. Prediction Accuracy for Irregular Cycles

Clue uses a statistical model that improves with more logged cycles. The company's own published research, including a 2019 study in npj Digital Medicine analyzing 1.5 million cycles, found that cycle length varies substantially across individuals and even within the same person across life stages. The study reported a median cycle length of 29.3 days, but with a standard deviation that means roughly 20 percent of cycles fall outside the 21 to 35-day range considered typical.

Women with PCOS, who may have cycles spanning 35 to 90 or more days, consistently report that Clue's default algorithm produces inaccurate predictions. The app does include a PCOS mode, but user feedback suggests it requires substantial manual adjustment to be useful. Women in perimenopause, whose cycles may shorten, lengthen, or skip unpredictably, face similar limitations. A 2020 cohort study in Menopause found that cycle variability increases significantly in the three to five years before the final menstrual period, exactly the window where algorithmic predictions based on historical patterns become least reliable.

Clinicians on the WomanRx editorial board note that no app, including Clue, has been validated specifically for perimenopausal cycle prediction in a prospective clinical trial. Women using cycle-tracking apps during perimenopause should treat predictions as rough guides rather than precise windows.

3. Data Loss After Account Issues

A smaller but notable complaint subset involves loss of years of cycle history following password resets, device changes, or account deactivation. Cycle history is medically meaningful data. If you have been logging cycles for three or more years, that longitudinal record can help a gynecologist identify patterns, document perimenopausal transition, or contextualize PCOS management. Losing it is a real clinical loss, not just an inconvenience.

Clue's support documentation recommends exporting data regularly, but the export function produces a CSV file that requires technical comfort to interpret. The company does not offer a one-click PDF health summary that a clinician could read directly.

4. Customer Support Response Times

Multiple review platforms document slow or templated responses from Clue's support team. Given that the company operates from Berlin, U.S. Users often experience timezone-related delays. For billing disputes that must be resolved within Apple's or Google's refund window, slow support responses can result in missed deadlines.

Privacy and Reproductive Health Data: A Post-Dobbs Consideration

Since the U.S. Supreme Court's 2022 Dobbs decision, the legal field around reproductive health data has changed in ways that are directly relevant to cycle-tracking app users. Some U.S. States have criminalized abortion provision or assistance, and there is theoretical legal exposure for individuals whose cycle data could be subpoenaed.

Clue has been notably direct on this issue. The company published a public statement in 2022 confirming that: (1) health data is stored in Germany, (2) U.S. Law enforcement requests would be subject to EU legal frameworks and German data protection law, and (3) Clue does not share health data with third parties. An independent 2023 privacy audit by the Future of Privacy Forum reviewed multiple femtech apps and found Clue to be among the more privacy-protective options, though the audit noted that no app can guarantee immunity from a sufficiently broad legal process.

Women in states with abortion restrictions who are tracking cycles for any purpose, including fertility awareness, PCOS management, or perimenopause documentation, should review Clue's current privacy policy before logging sensitive information. Switching to a local-storage-only app (one that stores data only on your device) eliminates cloud-based exposure entirely.

How Accuracy Varies by Life Stage

This is the area where Clue's marketing and its clinical utility diverge most sharply, and where women deserve a more honest accounting than they typically receive from app review sites.

Reproductive Years (Ages 18 to 40, Regular Cycles)

For women with regular, ovulatory cycles in the 24 to 38-day range, Clue's algorithm performs reasonably well after three to six months of data entry. A 2021 study in JMIR mHealth evaluated period prediction accuracy across four apps and found mean errors of two to three days for women with regular cycles. Clue was among the apps evaluated. For this group, the app is a practical tool for general awareness.

Trying to Conceive

Women actively trying to conceive should understand that Clue's standard cycle-tracking algorithm predicts ovulation based on historical cycle length, not on real-time physiological signals. This backward-looking approach can miss cycle-to-cycle ovulation shifts of three to five days, which are common even in women with otherwise regular cycles. The ASRM practice committee recommends that women trying to conceive for more than 12 months (or 6 months if over age 35) seek a formal fertility evaluation rather than relying on app-based timing alone.

Adding basal body temperature or urinary LH testing data to Clue entries meaningfully improves the utility of the app for cycle timing, because it shifts the app from historical estimation toward real-time physiological input.

PCOS

Women with PCOS represent one of Clue's most active user communities and one of its most underserved. PCOS affects approximately 6 to 12 percent of U.S. Women of reproductive age, and irregular cycles are a defining feature of the condition. An algorithm trained primarily on regular-cycle data produces systematically poorer predictions for this group. Clue's PCOS-specific features, including the ability to log androgen symptoms and anovulatory cycles, are a step forward, but the underlying prediction engine has not been validated in a PCOS-specific clinical trial.

Women with PCOS using Clue should prioritize the symptom-logging and pattern-documentation features rather than trusting the predicted fertile window for contraceptive or conception purposes.

Perimenopause

Perimenopause typically begins in the mid-to-late 40s and can last four to eight years. Cycle irregularity is the hallmark symptom. The Menopause Society (formerly NAMS) clinical practice guideline defines perimenopause as beginning with persistent cycle length changes of seven or more days from one cycle to the next. Clue can document these changes, which is genuinely useful for conversations with a gynecologist. What it cannot reliably do is predict the next period in a woman whose cycles are shifting from 28 to 45 days unpredictably.

Women in perimenopause should use Clue as a symptom and bleeding diary, not as a period-prediction tool. The app's note and symptom fields, when logged consistently, generate a clinically useful longitudinal record.

Postpartum

After delivery, cycles can resume as early as six weeks postpartum in non-breastfeeding women or be suppressed for months to over a year in exclusively breastfeeding women. Clue does not have a validated postpartum-specific algorithm. The app's predictions during postpartum are unreliable until at least two to three regular cycles have been logged. Women relying on any app for contraceptive guidance in the postpartum period should consult a clinician, as postpartum ovulation can precede the first visible period.

Who This App Is Right For, and Who Should Use It Cautiously

Good Fit

• Women with regular cycles who want a low-effort cycle log and symptom diary
• Women tracking general wellness symptoms across their cycle (energy, mood, skin)
• Women in perimenopause who want a longitudinal bleeding record for their gynecologist
• Women who prioritize EU-based data storage for privacy reasons

Use With Caution

• Women with PCOS using the fertile window feature for contraception: the standard app is not a validated contraceptive method
• Women trying to conceive: supplement with basal body temperature or LH testing
• Women in the postpartum period: predictions will be unreliable until cycles regularize
• Women in states with abortion restrictions who are concerned about data subpoena risk: review the current privacy policy and consider a local-storage alternative

Not Appropriate For

• Women seeking a primary contraceptive method: use Clue Birth Control (FDA-cleared) or a clinician-prescribed method, not the standard app
• Women with complex gynecologic conditions such as endometriosis or fibroids where precise cycle characterization affects treatment decisions: clinician-supervised tracking with validated tools is more appropriate

The Evidence Gap Women Deserve to Know About

Femtech research is improving, but cycle-tracking app accuracy has been studied far less rigorously than most women assume. The majority of published accuracy studies use retrospective app data rather than prospective clinical validation against confirmed ovulation (via ultrasound or serum progesterone). A 2020 systematic review in npj Digital Medicine examined 20 fertility awareness apps and found that only a minority had been validated against biological ovulation markers. Clue was not among those with prospective validation data at the time of that review.

This is not unique to Clue. It is a field-wide evidence gap. Women deserve to know that the accuracy figures cited by most cycle apps reflect internal algorithm testing or historical data modeling, not randomized controlled trials with confirmed ovulatory endpoints. As clinicians who advise patients on these tools, we owe honesty about that distinction.

"Women using digital health tools for reproductive decision-making deserve the same evidence standards we apply to any other health intervention," as stated in the ACOG Committee Opinion on Digital Health (CO 798). That standard is not yet met by most cycle-tracking apps, including Clue.

How to Get the Most Out of Clue Despite Its Limitations

Log daily, not retroactively. The algorithm improves with prospective data entry. Retrospective logging introduces recall bias and degrades prediction accuracy.

Use the note field clinically. Log headaches, bloating, libido changes, sleep disruption, and hot flashes if you are perimenopausal. This creates a symptom timeline your clinician can actually use.

Export your data every six months. Go to Settings > Data > Export Data and save the CSV to a secure location. If you lose account access, this backup is your only recovery option.

Do not cancel through the app alone. Manage your subscription through Apple or Google's native subscription management to avoid unintended renewal charges.

Pair with a physiological signal if you are tracking ovulation for any health purpose. Urinary LH strips or a basal body temperature thermometer integrated with Clue's manual entry fields add a real-time layer the algorithm alone cannot provide.